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Background: Negative attitudes towards insulin are commonly reported by people with type 2 diabetes mellitus
(T2DM) and can act as a barrier to timely insulin initiation. The Insulin Treatment Appraisal Scale (ITAS) is a widely used
20-item measure of attitudes towards insulin. While designed for completion by both insulin using and non-insulin using
adults with T2DM, its psychometric properties have not been investigated separately for these groups. Furthermore, the
total score is routinely reported in preference to the published two-factor structure (negative/positive appraisals). Further
psychometric validation of the ITAS is required to examine its properties.
Methods: The ITAS was completed by a subgroup of 748 Diabetes MILES – Australia study participants with T2DM, who
were either insulin using (n = 249; 45% women; mean age = 58 ± 9 years; mean diabetes duration = 13, SD = 8 years) or
non-insulin using (n = 499; 47% women; mean age 57 ± 9 years; mean diabetes duration 7 ± 6 years). We replicated the
psychometric analyses reported in the ITAS development paper. In addition, we explored factor structure and
investigated internal consistency separately for the insulin using and non-insulin using samples.
Results: Factor analyses supported a two-factor structure with good internal consistency (negative subscale α = .90;
positive subscale α = .69). Scale performance differed slightly in the insulin using and non-insulin using samples, with
some items loading inconsistently between groups. A one-factor solution was not supported in either sample, with the
positive items and some negative items failing to load adequately. Consistent with prior research, negative appraisals
were significantly more common among non-insulin using participants compared to those using insulin (d = 1.04),
while the positive subscale score did not discriminate between groups.
Conclusions: The data supported a two factor structure and the positive subscale did not discriminate between insulin
using and non-insulin using participants. As such, we recommend use of the negative subscale score in preference to
the ITAS total score, and suggest close attention is paid to the relevance of the positive items in the given population.
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Type 2 diabetes mellitus (T2DM) is a progressive condi-
tion and most people with this condition will eventually
require exogenous insulin to maintain haemoglobin A1c
within recommended targets [1,2]. However, a quarter of
adults with T2DM report being unwilling to begin insu-
lin therapy [3], commonly reporting concerns about the
necessity of insulin, as well as the physical, social and
symbolic adverse consequences of insulin use [4]. These
negative attitudes, known as ‘psychological insulin resist-
ance’ (PIR), may lead to delays in insulin initiation or
sub-optimal use once insulin is prescribed [3,5-8]. PIR is
a complex construct that does not simply equate to “fear
of the needle”, as people can base their reluctance to use
insulin on many different aspects of the therapy. The
construct has been operationalised through assessment
of attitudes toward insulin (insulin appraisal) [3,9-13].
Two scales have been developed and validated specific-
ally to measure attitudes towards insulin held by people
with T2DM. The 14-item ‘Barriers to Insulin Treatment’
(BIT) self-report questionnaire measures attitudes to-
wards insulin amongst people with non-insulin-treated
T2DM [13]. BIT items commonly refer to the physical
aspects of insulin use or technical concerns (e.g. side ef-
fects, pain) rather than the symbolic meaning of insulin
initiation (e.g. feelings of failure/self-blame or increased
diabetes severity). The Insulin Treatment Appraisal Scale
(ITAS) is a 20-item questionnaire, including 16 statements
referring to barriers to insulin use and four referring to its
benefits (12). Unlike the BIT, the more commonly used
ITAS was developed and validated for use by people with
T2DM regardless of current treatment type, with the ad-
vantage of enabling assessment both before and after insu-
lin initiation [12]. For non-insulin using respondents, the
ITAS assesses expectations about future insulin use, while
for those already using insulin, the measure is used to
evaluate actual experience with insulin use.
The clinical relevance of the ITAS has been demon-
strated. In cross-sectional studies, a difference has been
observed between insulin using and non-insulin partici-
pants in total ITAS scores of approximately one standard
deviation [12,14]. Longitudinal research indicates that the
ITAS is sensitive to treatment change from oral medica-
tion to insulin injections [15]. Furthermore, higher ITAS
scores (indicating more negative appraisal of insulin) are
associated with being hypothetically less ‘willing’ to begin
insulin if recommended [10]. Previous research has identi-
fied associations between ITAS scores and general and
diabetes-specific emotional wellbeing among people with
T2DM [12,16].
Initial investigation of the structure of the ITAS re-
vealed it to have a two-factor solution, identifying a posi-
tive subscale (benefits) and a negative subscale (barriers)
[12]. Despite reporting low item commonalities in aone-factor structure, scale developers proposed the use
of an ITAS total score (summation of all 20 items), to
indicate a person’s overall insulin appraisal. Since the
original US study [12], no further work has been pub-
lished regarding the validation of the two-factor or one-
factor structure, and the ITAS total score has been used
most commonly [9,10,16]. Despite reports that the ITAS
is psychometrically sound for both insulin using and
non-insulin using participants [12], psychometric ana-
lyses have not been reported separately for these groups.
Given that these groups may have either quantitatively
or qualitatively different attitudes towards insulin, based
on expectations or actual experience, an investigation is
needed of how the scale performs psychometrically in
each of these groups separately.
Further psychometric analyses are required to assess
the appropriateness of the scale in the two separate sam-
ples for which it was intended, as well as to further
evaluate the validity of the ITAS total score. Thus, our
aim was to further examine the psychometric properties
of the ITAS separately among insulin using and non-
insulin using adults with T2DM in Australia.
Methods
This analysis utilises a subset of data from Diabetes
MILES – Australia, a large-scale, national, cross-sectional
survey of Australian adults (aged 18 to 70 years) diagnosed
with either type 1 diabetes or T2DM. The survey was con-
ducted in July – August 2011. A detailed description of
the methods, response rates and questionnaires has been
published elsewhere [17]. Diabetes MILES – Australia re-
ceived ethics approval from the Deakin University Human
Research Ethics committee (reference number: 2011–046).
Participants
Diabetes MILES – Australia surveys were sent out to a ran-
dom sample of 15,000 National Diabetes Services Scheme
(NDSS) registrants. The NDSS register includes >1.1 million
registrants living with diabetes in Australia, of whom
87% have T2DM (http://www.ndss.com.au/en/Research/
Data-Snapshots/). Survey booklets were matched to the re-
corded diabetes diagnosis and treatment (confirmed at
registration by a health professional): T1DM, T2DM Insulin
using or T2DM non-insulin.
The survey was also made available online nationally,
with respondents required to self-report their type of
diabetes in order to receive the appropriate survey version.
The database was cleaned to validate survey versions
against self-report diabetes diagnosis, age at diagnosis, and
treatment type to ensure the highest level of accuracy pos-
sible given the self-report nature of the survey.
Overall, there were 3,338 eligible respondents, of
whom 1,962 reported living with T2DM. Of these, 49%
(n = 953) were women, the mean ± SD age was 59 ± 9
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analysis focuses on a subsample of participants with
T2DM who were invited to complete the ITAS [12] and
reported their diabetes treatment type as either insulin
using, requiring oral anti-hyperglycaemic tablets or fol-
lowing lifestyle recommendations. Participants reporting
use of glucagon-like peptide-1 (GLP-1) agonist treat-
ment were excluded from the current study. Like insulin,
GLP-1 agonist is administered via injection, but differs
from insulin use in a number of ways including, its effi-
cacy; potential side effects (e.g. weight loss versus pos-
sible weight gain when using insulin) [18]; and the
associated stigma of the treatment [19-22]. Therefore
participants using GLP-1 injections are not easily classi-
fied within either treatment group (insulin using and
non-insulin using) relevant to this study.
Measures
The Diabetes MILES – Australia surveys included a set of
core measures (completed by all respondents) and various
additional measures (included in one or more of the six
survey versions). Full details of the measures are published
elsewhere [17]. Variables of interest to this study include:
demographics (age, gender, relationship status, whether
employed in paid work, education level, and body mass
index), diabetes health status (self-reported diabetes type,
primary treatment and years living with diabetes), and the
ITAS [12].
The ITAS asks respondents to indicate their level of
agreement (‘strongly disagree’ = 1 to ‘strongly agree’ = 5)
with 20 statements. Scores for 16 negatively-worded
items are summed to provide a ‘negative appraisal’ score
(16–80); scores for four positively-worded items are
summed to provide a ‘positive appraisal’ score (4–20); all
twenty items are summed (with positively-worded items
reversed) to form a ‘total’ score (20–100). Higher ‘total’
and ‘negative appraisal’ scores indicate more negative at-
titudes, while higher ‘positive appraisal’ scores indicate
more positive attitudes towards insulin. Permission to
use the ITAS was granted by the copyright holders.
Statistical analysis
Statistical analysis was undertaken using SPSS version
21 (Chicago, USA). Frequencies, means and standard de-
viation were obtained for ITAS and relevant demograph-
ics for insulin using and non-insulin using participants.
Acceptability of the scale was assessed by examining
completion rates and identifying ceiling effects for nega-
tive ITAS items and floor effects for positive ITAS items
(i.e. >20% scoring minimum/maximum response) [23].
To replicate the methods described in the ITAS develop-
ment paper [12], we conducted exploratory factor ana-
lysis (EFA) with oblimin rotation on the 20-item scale
for the whole sample, as we expected the factors to becorrelated. When inspecting the Eigenvalues, we used
the Kaiser-criterion (Eigenvalue >1) and reviewed the
scree plot to determine the maximum number of factors.
In accordance with the original development paper, item
loadings were considered optimal if they were >0.40 on
one factor and <0.30 on any other factor [12]; a less con-
servative criterion of loading >0.30 (without concern for
double loadings) was also adopted [24]. To replicate the
hypothesised optimal scale structure, and to assess the
suitability of the total score, forced two-factor and one-
factor solutions were conducted respectively. Internal
consistency was estimated using Cronbach’s alpha and
Guttmans λ2 [25], where ≥0.70 and <0.90 was considered
reasonable. Item-total correlations were also calculated,
with a score of <0.20 taken to indicate a poor relationship
with the total scale score. These psychometric analyses
were conducted for the insulin-using and non-insulin
using samples separately and a forced one-factor solution
was also investigated.
Known-groups validity was explored by comparing
mean ITAS total, negative and positive scores between
treatment groups. Student t-tests or chi-squares were
conducted to assess between-groups differences in ITAS
scores. The association between demographics and total
ITAS scores between groups was explored using Student
t-tests and bivariate correlations. Statistical tests are
two-sided with differences accepted at a significant level
of p < 0.05. Effect sizes are reported using Cohen’s d.
Results
Overall, 887 participants with T2DM completed the
Diabetes MILES – Australia survey versions in which
the ITAS was included. Of these, 24 participants were
excluded due to unreported treatment type or reported
use of GLP-1 agonist injections. A further 115 (12.9%)
participants were excluded due to non-completion of at
least one ITAS item (see ‘Acceptability’ for further de-
tails). Of the 748 eligible respondents, one third were
using insulin to manage their diabetes. Participant char-
acteristics are shown in Table 1. Within the current
sample, 193 participants (26%) completed the online
version of the survey, and 555 (74.2%) completed the
hardcopy survey.
Acceptability
Non-insulin using participants were slightly more likely
to have missing data; 83 (14%) non-insulin participants
compared to 32 (11%) insulin-using participants missed
at least one item. Of the non-insulin using participants
with missing data, almost half (n = 39) skipped all 20 items.
Thirty-three missed just one item and the remaining 11
missed between 2 and 19 items. The majority of insulin
using participants with missing data skipped only 1 item
(n = 26), and a further six skipped between 2 and 15 items:
Table 1 Self-reported demographics and clinical
characteristics of insulin using and non-insulin using
participants
Non-insulin users Insulin users
N (%) 499 (67%) 249 (33%)
Female sex 233 (47%) 112 (45%)
Age - years 57 ± 9 (22 – 70) 58 ± 9 (21 – 70)
Employment - in paid work 279 (56%) 104 (42%)
Education
Low 32 (7%) 36 (16%)
Medium 314(66%) 157 (67%)
High 132 (28%) 40 (17%)
Having a partner 369 (75%) 178 (73%)
Diabetes duration - years 7 ± 6 (<1 – 35) 13 ± 8 (<1 – 42)
Primary Treatment
Lifestyle modifications 130 (26%) -
Blood glucose lowering tablets 369 (74%) -
Insulin injections - 247 (99%)
Insulin pump - 2 (1%)
BMI 31 ± 7 (13 – 78) 34 ± 9 (15 – 92)
NB. Valid percentage reported as n values vary due to missing data on
individual variables.
Data are mean ± standard deviation or N (%).
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the whole scale, each of the 20 ITAS items was completed
by ≥98.2% of non-insulin using participants and, similarly,
by ≥98.2% of insulin using participants.
Among the four positively-worded ITAS items, no floor
effects were apparent amongst either insulin or non-
insulin using participants (i.e. ≤20% of participants
strongly disagreed with the benefits of insulin). Ceiling
effects were apparent for four of the 16 negatively
worded items among non-insulin using participants
(>20% and <32% strongly agreed with items 1, 2, 5 and 6)
but none were apparent among insulin using participants.
Scale structure: whole sample
EFA analyses conducted on the whole sample revealed a
maximum of four factors with an Eigenvalue >1, explain-
ing 57.1% of the total variance. The Eigenvalue for (and
variance explained by) each factor respectively was 6.7
(33.4%), 2.3 (11.7%), 1.3 (6.4%), and 1.1 (5.7%). Factors
three and four were most easily interpretable: the four
‘benefits’all loaded onto one factor suggesting a ‘positive
appraisal’ subscale, and the two side-effect items (‘in-
creases risk of hypoglycaemia’ ‘weight gain’) loaded onto
another factor. Eleven negative appraisal items loaded
onto the first factor with the remaining three loading onto
the second factor, with no clear interpretation for either.
Given the minimal additional variance explained by a
3- or 4-factor solution, and the aim to replicate the scalestructure previously reported [12], a three-factor solu-
tion was not investigated. The two-factor solution ex-
plained 45% of the total variance with the first factor
including all negatively-worded items except ‘weight
gain’ and the second factor including the four positively-
worded items. Only item 18 (‘family and friends concerns’)
loaded >0.3 on more than one factor. The correlation be-
tween factors was low (r = 0.06), suggesting a Varimax ro-
tation would be more suitable, but the results of this
rotation did not differ from the loading pattern obtained
using the oblique rotation. A forced one-factor solution
explained 33.4% of the variance, with all four positive
items and the ‘weight gain’ item failing to load sufficiently.
Overall, reliability was satisfactory for the 20-item scale
(α = 0.87; λ2 = 0.89), the 16-item negative subscale (α = 0.90;
λ2 = 0.91), and for the positive subscale (α = 0.69; λ2 = 0.69).
Table 2 displays both the forced one-factor and two-factor
solutions, with item loadings for the whole sample (de-
scribed here) and by treatment type (described below).
Scale structure: by treatment type
In the non-insulin using sample, inspection of the
Eigenvalues after EFA revealed a maximum of four fac-
tors, explaining 57.2% of the total variance. The Eigenvalues
for (and variance explained by) each factor respectively
was 6.4 (32.0%), 2.6 (12.9%), 1.4 (6.8%), and 1.1 (5.4%).
Only factor four was interpretable, with all four ‘bene-
fits’loading >0.4, suggesting a ‘positive appraisal’ sub-
scale. Item 7 (‘increased risk of hypoglycaemia’) did not
load >0.4 on any factor and six other items loaded ≥ ±0.3
onto more than one factor.
An EFA conducted for the insulin using participants
revealed a maximum of five factors, explaining 57% of
the total variance. The Eigenvalues for (and variance ex-
plained by) each factor respectively was 5.4 (27.0%), 2.2
(10.9%), 1.5 (7.7%), 1.2 (6.1%), and 1.0 (5.2%). Once
more, one factor included satisfactory loadings for all
four positive items while the other factors were unclear.
Ten items loaded ≥ ±0.3 on two or more factors and two
items did not load at all (‘weight gain’ and ‘concern from
family and friends’).
The two-factor solution within the non-insulin using
group explained 44.9% total variance, with the first fac-
tor including 15 of the 16 negative items, and the second
factor including all four positive items. Item 7 (‘increases
risk of hypoglycaemia’) did not load on either factor, or
four of the negative items double-loaded (≥ ± 0.3) on
both factors. Amongst the insulin using group, a two-
factor solution explained 38% variance. Factor one in-
cluded all 16 negative items and factor two included the
four positive items.
A forced one-factor solution explained 32% and 27%
of the total variance in the non-insulin using and insulin
using samples respectively. The positive items did not
Table 2 Forced 1-factor and 2-factor EFA of the ITAS: whole sample and by treatment type




















1 Taking insulin means I have failed to manage my
diabetes with diet and tablets
0.55 0.54 0.54 0.48 0.40 0.37
2 Taking insulin means my diabetes has become
much worse
0.60 0.59 0.59 0.48 −0.38 0.43 0.39
3^ Taking insulin helps to prevent complications of
diabetes
0.69 0.71 0.57
4 Taking insulin means other people see me as a
sicker person
0.65 0.64 0.64 0.54 −0.36 0.59 0.59
5 Taking insulin makes life less flexible 0.72 0.71 0.70 0.60 −0.33 0.64 0.69
6 I'm afraid of injecting myself with a needle 0.65 0.66 0.58 0.60 0.52 0.51
7 Taking insulin increases the risk of low blood
glucose levels (hypoglycaemia)
0.44 0.43 0.37 0.47 0.47
8^ Taking insulin helps to improve my health 0.76 0.72 0.81
9 Insulin causes weight gain 0.43 0.43 0.37 0.37
10 Managing insulin injections takes a lot of time
and energy
0.74 0.74 0.69 0.70 0.68 0.69
11 Taking insulin means I have to give up activities
I enjoy
0.72 0.73 0.70 0.74 0.67 0.69
12 Taking insulin means my health will deteriorate 0.70 0.72 0.66 0.73 0.71 0.66
13 Taking insulin is embarrassing 0.71 0.73 0.69 0.78 0.70 0.71
14 Injecting insulin is painful 0.71 0.72 0.69 0.74 0.65 0.66
15 It is difficult to inject the right amount of insulin
correctly at the right time every day
0.68 0.69 0.67 0.71 0.51 0.50
16 Taking insulin makes it more difficult to fulfil my
responsibilities (at work, at home)
0.79 0.80 0.75 0.80 0.73 0.71
17^ Taking insulin helps to maintain good control of
my blood glucose
0.74 0.73 0.74
18 Being on insulin causes family and friends to be
more concerned about me
0.59 0.56 −0.32 0.60 0.47 −0.42 0.40 0.48
19^ Taking insulin helps to improve my energy levels 0.55 0.50 0.63
20 Taking insulin makes me more dependent on
my doctor
0.62 0.61 0.64 0.58 0.48 0.51
Cronbach’s alpha 0.87 0.90 0.69 0.85 0.89 0.69 0.84 0.85 0.68
Total variance explained 33.4% 45% 32% 44.9% 27.0% 38%
NB. EFA conducted using oblimin rotation. Loadings < ±0.30 have been suppressed from the table for clarity of interpretation.
^positive ITAS items.
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negative items except for item 7 (‘increases risk of
hypoglycaemia’), loaded onto the factor and in the insu-
lin using sample only item 9 (‘weight gain’) did not load.
In the non-insulin using sample, Cronbach’s alpha
was 0.85 for the 20-item scale, 0.89 for the 16-item
negative subscale, and 0.69 for the positive subscale.
Guttmans λ2 was 0.87, 0.90, and 0.71 respectively. In-
ternal consistency was similar for insulin using partici-
pants: for the total scale α = 0.84 and λ2 = 0.85, for the
negative subscale α = 0.85 and λ2 = 0.87, and for the
positive subscale α = 0.68 and λ2 = 0.69.Within the total scale, all positive items displayed
low item-total correlations; <0.1 for non-insulin partic-
ipants and <0.32 for insulin using participants. All
item-total correlations for negatively worded items
were >0.2 for both non-insulin and insulin using par-
ticipants. When exploring the negative and positive
subscales separately, all item-total correlations were
above the >0.2 cut off for non-insulin using partici-
pants (negative subscale range = 0.31-0.69, positive
subscale range = 0.36-0.58) or for insulin using partici-
pants (negative subscale range = 0.35- 0.63, positive
subscale range = 0.38-0.58).
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Table 3 displays, by treatment type, the mean and stand-
ard deviation for each of the ITAS items, total score, posi-
tive subscale and negative subscale, the t-test significance
results and effect sizes showing between group differ-
ences, as well as the percentage who agreed or strongly
agreed with each item. Non-insulin using participants
reported significantly higher (more negative) scores com-
pared to the insulin using participants on all negatively-
worded items, except for ‘insulin causes weight gain’, for
which insulin using participants reported higher (more
negative) scores. Moderate effect sizes were found be-
tween groups for 9 of the 16 negative items (d range =
0.54-0.76), and large effect sizes for 4 items (d range =
0.86-1.08). Item 6 (‘I’m afraid of injecting myself with a
needle’) discriminated most highly between groups.
There were significant differences between treatment
groups for the negative subscale (t (746) = 13.44, p < 0.001,
d = 1.04) and total ITAS score (t (746) = 13.05, p < 0.001,
d = 1.03). The percentage of participants who agreed with
the benefits of insulin was high, regardless of treatmentTable 3 Differences in ITAS scores (items, subscales, and tota
Item
1 Taking insulin means I have failed to manage my diabetes with diet a
2 Taking insulin means my diabetes has become much worse
3^ Taking insulin helps to prevent complications of diabetes
4 Taking insulin means other people see me as a sicker person
5 Taking insulin makes life less flexible
6 I'm afraid of injecting myself with a needle
7 Taking insulin increases the risk of low blood glucose levels (hypogly
8^ Taking insulin helps to improve my health
9 Insulin causes weight gain
10 Managing insulin injections takes a lot of time and energy
11 Taking insulin means I have to give up activities I enjoy
12 Taking insulin means my health will deteriorate
13 Taking insulin is embarrassing
14 Injecting insulin is painful
15 It is difficult to inject the right amount of insulin correctly at the right
16 Taking insulin makes it more difficult to fulfil my responsibilities (at w
17^ Taking insulin helps to maintain good control of my blood glucose
18 Being on insulin causes family and friends to be more concerned abo
19^ Taking insulin helps to improve my energy levels




M: mean; SD: standard deviation; A/SA: Agree/Strongly Agree; ^ positive ITAS items
Scoring: 1 = Strongly Disagree, 5 = Strongly Agree.type, and the mean positive subscale score was not signifi-
cantly different between groups (t (746) = 0.55, p = 0.582,
d = 0.04).
Associations between ITAS scores and demographics
were comparable between groups. Total ITAS scores were
weakly positively correlated with age for both insulin
users (r = −0.29, p < 0.001) and non-insulin users (r = −0.18,
p < 0.05). No significant relationship was apparent between
ITAS scores and diabetes duration for either group
(both p > 0.607). Between group ITAS scores did not
differ by gender (p > 0.558 for both) or whether partici-
pants reported being in a relationship (p > 0.118 for
both). Both insulin users (t (247) = −2.17, p = 0.03) and
non-insulin users (t (494) = −3.65, p < 0.001) who partici-
pated in paid work reported significantly higher ITAS
scores (more negative) than those not in paid work.
Discussion
In replication of the ITAS development paper [15], EFA
and reliability tests were conducted on the whole sam-
ple and similar results were observed. However,l score) by insulin use
Non-insulin users Insulin users d
M ± SD A/SA% M± SD A/SA%
nd tablets 3.5 ± 1.3 58.3% 2.8 ± 1.3*** 39.4% 0.54
4.0 ± 1.0 80.2% 3.2 ± 1.2*** 51.0.0% 0.76
3.9 ± 1.0 76.4% 3.9 ± 1.0 76.7% 0.04
3.3 ± 1.1 46.3% 2.7 ± 1.1*** 26.1% 0.53
3.6 ± 1.1 58.7% 2.8 ± 1.1*** 28.9% 0.71
3.3 ± 1.4 47.9% 1.9 ± 1.2*** 10.4% 1.08
caemia) 3.4 ± 1.0 46.5% 3.0 ± 1.1*** 36.1% 0.45
3.8 ± .08 67.7% 3.9 ± 0.9 75.5% −0.12
3.1 ± .08 18.2% 3.5 ± 1.0*** 50.6% −0.47
3.3 ± 1.0 40.9% 2.4 ± 1.1*** 15.3% 1.04
2.7 ± 1.0 16.8% 2.1 ± 1.0*** 6.4% 0.63
2.8 ± 1.0 18.6% 2.2 ± 1.0*** 9.2% 0.57
2.7 ± 1.1 21.6% 2.2 ± 1.1*** 14.9% 0.48
3.1 ± 1.0 32.1% 2.4 ± 1.1*** 18.9% 0.67
time every day 3.0 ± 0.9 23.2% 2.1 ± 1.0*** 12.4% 0.86
ork, at home) 2.8 ± 0.9 17.8% 2.0 ± 0.9*** 4.8% 0.92
3.9 ± 0.8 74.7%% 3.9 ± 0.9 78.7% −0.05
ut me 3.6 ± 0.9 57.7% 3.0 ± 1.0*** 33.7% 0.65
3.3 ± 0.7 30.9% 3.1 ± 0.9** 30.5% 0.28
3.4 ± 0.9 47.3% 2.9 ± 1.1*** 33.7% 0.54
60.7 ± 10.1 50.2 ± 10.3*** 1.03
14.9 ± 2.4 14.8 ± 2.6 0.04
51.6 ± 10.2 41.2 ± 9.6*** 1.04
, **p < .01, ***p < .001.
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single ‘Total ITAS’ score, we believe the two-factor struc-
ture appears to be a better representation of the 20-
item scale, with only ‘weight gain’ not loading on either
scale.
In exploring the two-factor solution for the insulin using
and non-insulin using samples separately, we found vari-
ation in some item loadings. For non-insulin using partici-
pants, item 7 (‘increases risk of hypoglycaemia’) did not
load onto either subscale. This might be due to a lack of
knowledge among non-insulin using participants regard-
ing the potential risk of hypoglycaemia caused by insulin
use, though almost half of this sample agreed or strongly
agreed that this was a risk. In contrast to the whole
sample, item 9 (‘weight gain’) loaded onto the negative
subscale for non-insulin users and a number of other
variables (items 2, 4, 5, 18) had multiple loadings, while
all loading strongest on the negative subscale. Only
item 18 loaded >0.4 on both the positive and negative
subscale. This might be explained by non-insulin using
participants feeling that insulin causing “family and
friends to be more concerned about me” would in fact
be a benefit of insulin use. Indeed, the item wording is
not sufficiently negative for the direction to be clear.
For insulin using participants, items 1 (‘insulin means
my previous self-care has failed’), 2 (‘insulin means my
diabetes is worse’) and 9 (‘weight gain’) were just shy of
loading onto the negative subscale (if a stringent criter-
ion of >0.4 was applied) but loaded well when a less
conservative criterion (>0.3) was adopted. However
these items were the three most highly endorsed among
insulin using participants, which suggests they should
not be removed from the scale. The forced two-factor
solution was the best representation of the 20-item
questionnaire for both samples.
Reliability of negative and positive subscales was
similar between groups, with the high negative subscale
alpha suggesting the possibility for scale reduction. A
small number of items performed inconsistently be-
tween treatment groups. They maybe candidates for re-
moval or it may be that different items are important
for different treatment groups. These items (1, 2, 7,
and 9), which also had lower item-total correlations
and did not load consistently, were often more highly
endorsed by participants than those which performed
better statistically, suggesting they have strong face val-
idity. It may be that these items are not performing sta-
tistically as well because they are conceptually quite
independent of other negative aspects of insulin use,
while the items that load well and display high item-
total correlations frequently refer to similar barriers to
insulin (e.g. the burden of insulin injections in terms of
its effect on lifestyle and responsibilities, as well the
technical/physical aspects of having to inject).Given the high internal consistency reliability of the
20-item total scale, the ITAS total score has been recom-
mended for use to quantify overall insulin appraisal [12].
However, in both the ITAS development paper and our
current study, Cronbach’s alpha for the 20-item scale is
lower than for the 16-item negative scale, and the posi-
tive items display very low item-total correlations. Un-
surprisingly, a forced one-factor EFA reveals that the
four positive items do not load on the factor for either
treatment group. Given these results, we propose that
the positive and negative subscales should not be com-
bined to create a total score.
Consistent with international findings adults with non-
insulin-treated T2DM report significantly more negative
attitudes towards insulin use than those using insulin,
with total ITAS scores differing by approximately one
standard deviation [12,14,15]. Non-insulin using partici-
pants reported higher (more negative) scores on 15 of
the 16 items, with ‘weight gain’ the only item for which
insulin using participants reported more negative ap-
praisals. This is also consistent with previous research
[12,14]. With the exception of ‘weight gain’, the ranking
of negative appraisals was similar between the two treat-
ment groups; suggesting similar prioritisation of con-
cerns about insulin between groups and differing only by
intensity of endorsement. Ceiling effects were present
for four ITAS items among non-insulin using partici-
pants, but not for the insulin using participants. How-
ever, as these ceiling effects are moderate (<33%), are in
line with the expected scoring direction of non-insulin
using participants, and not displayed among insulin
using participants, we suggest that they may not be
cause for concern necessarily.
While the ‘negative appraisal’ subscale showed strong
discriminatory power, the positive subscale did not differ
between treatment groups. Similar to previous studies,
we found that participants not using insulin commonly
endorsed positive statements about insulin [9,10,12,14,15].
This suggests that concerns about insulin initiation, or
psychological insulin resistance, may exist independently
of the belief that insulin may be beneficial. This may have
implications for clinical care. For example, when counsel-
ling patients about their diabetes management options, it
may be more beneficial to acknowledge, normalise and
then minimise their perceived barriers to insulin use ra-
ther than emphasising only the actual benefits of insu-
lin use. However, we recommend that the positive
items are retained in the scale for further research pur-
poses such as exploring the subscales association with
other variables (e.g. self-care behaviours, optimal insu-
lin taking behaviours). For example, previous research
has reported optimal medication taking behaviours to
be associated with belief in the benefit of the medica-
tion [26].
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The strengths of this study include it being the first
study to quantitatively explore PIR in an Australian sam-
ple using a validated measure. In addition, it is the only
study to further evaluate the psychometric performance
of the ITAS since its development. The large sample size
and the inclusion of both insulin using and non-insulin
using participants to enable separate psychometric ana-
lyses are also advantages.
The limitations of Diabetes MILES – Australia are dis-
cussed in detail elsewhere [17]. Limitations of specific
relevance to the current study are the self-report nature
of the diabetes diagnosis for 26% of the sample and the
proportion of missing data. The ITAS was developed
and validated for use among people with T2DM. Given
the self-report nature of Diabetes MILES – Australia, it
is impossible to tell whether all participants were accur-
ately classified as having type 2 diabetes. However, it is
expected that the following safeguards reduced the likeli-
hood of participants being misclassified. The majority
(74%) of respondents had received a pre-determined sur-
vey booklet type (specific to their diabetes type and
treatment) based on their diabetes diagnosis as reported
within in the NDSS [17]. These participants had the op-
portunity to complete the ITAS only if they were regis-
tered with the NDSS as having a diagnosis of T2DM;
their data were removed from the current analysis if they
subsequently reported a diagnosis of type 1 diabetes
within the survey booklet. Online participants (26%) re-
ceived the ITAS for completion only if they self-reported
living with T2DM. Thus, any participant who received a
type 1 booklet or self-reported online that they had type
1 diabetes would not have had the opportunity to
complete the ITAS. Prior literature concludes that self-
reported diabetes diagnosis, not type specific, is reason-
ably accurate when compared to medical data [27,28].
However, to the author’s knowledge, no research has ex-
plored the validation of self-reported diabetes type com-
paring those with type 1 and those with T2DM.
A further limitation of the current analysis was the
missing data, which differed by treatment group, sug-
gesting that the scale may be more acceptable or rele-
vant to participants with T2DM using insulin than non-
insulin using participants. It is probable that those
non-insulin using participants who skipped the scale
entirely perceived it to be irrelevant for them, despite in-
structions asking non-insulin users “to answer each item
based on their current knowledge and thoughts about
what insulin therapy would be like”. Hence, we advise fu-
ture ITAS users to consider including instructions that
better emphasise that the questionnaire is to be comple-
ted by all participants, not just those already using insulin.
After excluding participants who skipped the entire ques-
tionnaire, almost three quarters of those with missing dataskipped just one item and no particular item displayed
substantial non-completion. This indicates acceptability of
items among the majority of participants.
Finally, the wording of some ITAS items assumes
current or prior use of lifestyle modifications or blood
glucose lowering tablets. However, it is possible that a
proportion of participants with insulin-treated T2DM
have not actively managed their diabetes prior to begin-
ning insulin, and therefore, may find some ITAS ques-
tions inappropriate. For example: “Taking insulin means
I have failed to manage my diabetes with diet and tab-
lets”. As the Diabetes MILES survey did not ask partici-
pants to report previous diabetes treatments, we are
unable to clarify what proportion, if any, were prescribed
insulin immediately after diagnosis of T2DM. This is a
potential limitation of the questionnaire and we recom-
mend that future users consider including assessment of
prior diabetes management.
Conclusions
In the present study, the 20-item ITAS total score explained
less variance and displays lower internal consistency reli-
ability than the 16-item ‘negative appraisal’ score. We rec-
ommend that calculation of the 20-item ITAS total score
be avoided in preference for the 16-item ‘negative appraisal’
score, with close attention paid to the relevance and useful-
ness of the ‘positive appraisal’ subscale in the given popula-
tion. Our findings support use of the ITAS in both
treatment groups. As perceptions of insulin use appear to
vary based on expectation versus actual experience, it is un-
surprising that certain items performed inconsistently be-
tween groups. The ITAS is a relatively brief and easy to
complete questionnaire which may be useful clinically to
promote discussion with people with T2DM about their
concerns regarding insulin use, or to evaluate interventions
to reduce PIR.
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